HMPV in Focus: Emerging Insights into a Silent Respiratory Threat

Human Metapneumovirus (HMPV) is a major cause of respiratory illness, primarily affecting young children, and can also cause severe disease in elderly or immunocompromised adults. Although first identified in 2001, retrospective studies suggest HMPV has been circulating since at least 1958, with its late discovery attributed to challenges in culturing the virus. HMPV is closely related to avian pneumovirus, indicating a possible evolutionary link, and belongs to the Metapneumovirus genus, which includes Respiratory Syncytial Virus (RSV). Both viruses cause similar respiratory conditions, making clinical differentiation difficult. HMPV infections lead to bronchiolitis, pneumonia, and other respiratory symptoms, particularly in children. Diagnosis is typically made through PCR or viral culture, as symptoms alone are insufficient for distinguishing HMPV from RSV. There is no specific antiviral treatment for HMPV; management focuses on supportive care, including oxygen therapy and hydration in severe cases. Preventative strategies include good hygiene practices and monoclonal antibody therapy for high-risk individuals. Understanding the etiology, diagnosis, and treatment of HMPV is crucial for addressing its impact on public health, especially in vulnerable populations.